Medicon Valley Academy Drug Development network

8 September 2004 / Öresundshuset / Copenhagen

 

The first formulated trial product - quick fix or strategic decision?

For the first preclinical trials of a project conducted in an emerging pharma or biotech company, little attention is paid to the formulation. For good reasons, the simplest possible formulation may be chosen, or perhaps the whole issue is left to a CRO to decide upon.

 

However, eventually there will come a time when the choice of formulation will have a significant effect not just on the outcome of a trial, but also on the subsequent conclusions and decisions for the continued project. "Would the bioavailability have been acceptable with another formulation?", is a question you would rather avoid after completing your first human trial. On the other hand, there may also be cases where it is advisable not to include advanced formulation science in your product at an early stage, as it may repel potential licensees at a later stage.

 

These and other, related issues are treated in the presentation, which will also present a brief inventory over regional service or technology providers in the field of formulations and drug delivery.

 

Speaker

Bengt Westrin, Ph.D., Assoc. Prof. Vice President, Business Development from Camurus AB.

 

Venue

Öresundshuset, Gammel Kongevej 1, third floor, Copenhagen, Denmark.

 

When?
8 September, 2004  15.30-17.30

 

Registration fee
MVA members: Free

Non members: 300 DKK

 

Registration

Anette Andersson, aa@mva.org

Registration deadline 3 September 2004

 

More information

Anette Andersson, aa@mva.org, +46 46 286 3321 or Stina Gestrelius, sg@mva.org, +46 46 286 33 23.

 

Read more about the Medicon Valley Academy Drug Development Network